Taha Z. Sen

Groningen, GR, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Effects of albuminuria-lowering treatments on inflammation markers: A post hoc analysis from the ROTATE trials.

Effects of albuminuria-lowering treatments on inflammation markers: A post hoc analysis from the ROTATE trials.

Journal: Diabetes, obesity & metabolism

Published: December 13, 2022

Sodium glucose co-transporter 2 inhibition increases epidermal growth factor expression and improves outcomes in patients with type 2 diabetes.

Sodium glucose co-transporter 2 inhibition increases epidermal growth factor expression and improves outcomes in patients with type 2 diabetes.

Journal: Kidney international

Published: October 18, 2022

Optimization of Albuminuria-Lowering Treatment in Diabetes by Crossover Rotation to Four Different Drug Classes: A Randomized Crossover Trial.

Optimization of Albuminuria-Lowering Treatment in Diabetes by Crossover Rotation to Four Different Drug Classes: A Randomized Crossover Trial.

Journal: Diabetes care

Published: August 31, 2022

Updated guidelines for gene nomenclature in wheat.

Updated guidelines for gene nomenclature in wheat.

Journal: TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik

Published: May 25, 2022

Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS.

Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS.

Journal: Diabetes care

Published: May 03, 2022

Mechanisms of action of the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial.

Mechanisms of action of the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial.

Journal: Diabetes, obesity & metabolism

Published: March 16, 2022

Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND.

Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND.

Journal: Diabetes, obesity & metabolism

Published: March 15, 2022

Association Between Circulating GDF-15 and Cardio-Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial.

Association Between Circulating GDF-15 and Cardio-Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial.

Journal: Journal of the American Heart Association

Published: December 02, 2021

Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease.

Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: June 25, 2021

Yippee like 4 (Ypel4) is essential for normal mouse red blood cell membrane integrity.

Yippee like 4 (Ypel4) is essential for normal mouse red blood cell membrane integrity.

Journal: Scientific reports

Published: May 07, 2021

Decreased PGC1β expression results in disrupted human erythroid differentiation, impaired hemoglobinization and cell cycle exit.

Decreased PGC1β expression results in disrupted human erythroid differentiation, impaired hemoglobinization and cell cycle exit.

Journal: Scientific reports

Published: March 16, 2021

Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial.

Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial.

Journal: Diabetologia

Published: December 28, 2020

Showing 1-12 of 14

Last Updated: 09/26/2026